Articles by tag: oncology-trends

Breakthrough technologies in oncology: shift to PROTAC and CAR-T

Nature records a paradigm shift: oncology moves from inhibitors to PROTAC and cell therapy. Find out who wins in the new race and what awaits the market.

Vepdegestrant: FDA approved the first PROTAC degrader

FDA approved Vepdegestrant — the first protein degrader tablet for ESR1-mutant breast cancer. PFS 5 months vs 2.1 for fulvestrant. Learn why this is a paradigm shift.